Nyxoah who are a health-technology company focused on the development and commercialisation of innovative solutions and services to treat sleep disordered breathing conditions, has announced on Thursday the results of its initial public offering of new shares.
This was launched on 9 September 2020, with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol “NYXH.”
The final offering price for the offering has been set at €17.00 per share, giving the company an initial market capitalization of approximately €364.21m, or approximately €375.26m assuming the exercise in full of the Over-allotment Option.
Gross proceeds for the company from the IPO will amount to approximately €73.70m, or approximately €84.75m, assuming the exercise in full of the Over-allotment Option.
Olivier Taelman, Chief Executive Officer of Nyxoah said, “The successful IPO of Nyxoah validates the unique and disruptive character of the Nyxoah solution for Obstructive Sleep Apnea and confirms the existing unmet need in this large and growing global OSA market.
“The concrete strong interest from leading global investors in combination with the continued support of the existing investors will enable the Company to further execute on its strategy. We warmly welcome the new investors and thank the existing ones for their trust.”
Robert Taub, Founder and Chairman of Nyxoah added, “When founding the Company in 2009, the ambition was to develop a unique patient-centered solution to help OSA patients enjoy their lives to the fullest. The overwhelming enthusiasm of new and existing investors in this Offering will help us further to fulfill this vision. We are looking forward to this new phase in Nyxoah’s development under the leadership of our CEO.”